Junlin Zhuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junlin Zhuo has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Kar Lun Leung
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
2 shared publications Anthony R. Fehr
Department of Molecular Biosciences, University of Kansas, Lawrence, USA
2 shared publications- Jürgen Bosch
Case Western Reserve University
2 shared publications - Takashi Tsukamoto
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
2 shared publications Ajit Thomas
Johns Hopkins Drug Discovery, Baltimore, Maryland 21205, United States
1 shared publication- Alessandro Panattoni
SigutLabs, Praha, Czech Republic
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 3 March 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (4) , 812-826
Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control
Antiretroviral therapy (ART) interruption typically leads to rapid HIV-1 viral rebound in people with HIV-1. To develop an HIV-1 cure, insight into immunological mechanisms capable of preventing HIV-1 viral rebound is urgently needed. Here, we describe three exceptional post-intervention controllers (PICs) who maintained ART-free virological control for >6.5 years (ongoing), >7.5 years (ongoing) and 2.5 years following administration of broadly neutralizing antibodies. PICs had quantifiable genetically intact/inducible infectious proviral reservoirs that were increasingly clonal and located in nongenic/centromeric chromosomal regions, indicating immune-mediated selection. Potent autologous neutralizing antibodies and polyfunctional HIV-1-specific CD4 + and CD8 + T cell responses, pre-programmed for antigen response, were present before, and persisted during, ART interruption. In one PIC, viral rebound following 2.5 years of ART-free control was associated with accumulated viral mutations that resulted in escape from neutralizing antibody and T cell responses. Collectively, our findings support developing HIV-1 curative strategies aimed at enhancing pre-existing adaptive immune responses.
- 3 March 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (4) , 812-826
Top Cited PapersOpen AccessAutologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control
Antiretroviral therapy (ART) interruption typically leads to rapid HIV-1 viral rebound in people with HIV-1. To develop an HIV-1 cure, insight into immunological mechanisms capable of preventing HIV-1 viral rebound is urgently needed. Here, we describe three exceptional post-intervention controllers (PICs) who maintained ART-free virological control for >6.5 years (ongoing), >7.5 years (ongoing) and 2.5 years following administration of broadly neutralizing antibodies. PICs had quantifiable genetically intact/inducible infectious proviral reservoirs that were increasingly clonal and located in nongenic/centromeric chromosomal regions, indicating immune-mediated selection. Potent autologous neutralizing antibodies and polyfunctional HIV-1-specific CD4 + and CD8 + T cell responses, pre-programmed for antigen response, were present before, and persisted during, ART interruption. In one PIC, viral rebound following 2.5 years of ART-free control was associated with accumulated viral mutations that resulted in escape from neutralizing antibody and T cell responses. Collectively, our findings support developing HIV-1 curative strategies aimed at enhancing pre-existing adaptive immune responses.
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
Cellular engagement of the SARS-CoV-2 macrodomain by GS-441524 and enhanced in vitro inhibition by its diphosphorylated metabolite
GS-441524, the parent nucleoside of remdesivir, engages the SARS-CoV-2 macrodomain (Mac1) in cells, and its diphosphate metabolite exhibits enhanced inhibitory activity.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
Open AccessCellular engagement of the SARS-CoV-2 macrodomain by GS-441524 and enhanced in vitro inhibition by its diphosphorylated metabolite
GS-441524, the parent nucleoside of remdesivir, engages the SARS-CoV-2 macrodomain (Mac1) in cells, and its diphosphate metabolite exhibits enhanced inhibitory activity.
- 14 December 2021
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 17 (1) , 17-23
High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain
Macrodomains are a class of conserved ADP-ribosylhydrolases expressed by viruses of pandemic concern, including coronaviruses and alphaviruses. Viral macrodomains are critical for replication and virus-induced pathogenesis; therefore, these enzymes are a promising target for antiviral therapy. However, no potent or selective viral macrodomain inhibitors currently exist, in part due to the lack of a high-throughput assay for this class of enzymes. Here we developed a high-throughput ADP-ribosylhydrolase assay using the SARS-CoV-2 macrodomain Mac1. We performed a pilot screen that identified dasatinib and dihydralazine as ADP-ribosylhydrolase inhibitors. Importantly, dasatinib inhibits SARS-CoV-2 and MERS-CoV Mac1 but not the closest human homologue, MacroD2. Our study demonstrates the feasibility of identifying selective inhibitors based on ADP-ribosylhydrolase activity, paving the way for the screening of large compound libraries to identify improved macrodomain inhibitors and to explore their potential as antiviral therapies for SARS-CoV-2 and future viral threats.
- 14 December 2021
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 17 (1) , 17-23
High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain
Macrodomains are a class of conserved ADP-ribosylhydrolases expressed by viruses of pandemic concern, including coronaviruses and alphaviruses. Viral macrodomains are critical for replication and virus-induced pathogenesis; therefore, these enzymes are a promising target for antiviral therapy. However, no potent or selective viral macrodomain inhibitors currently exist, in part due to the lack of a high-throughput assay for this class of enzymes. Here we developed a high-throughput ADP-ribosylhydrolase assay using the SARS-CoV-2 macrodomain Mac1. We performed a pilot screen that identified dasatinib and dihydralazine as ADP-ribosylhydrolase inhibitors. Importantly, dasatinib inhibits SARS-CoV-2 and MERS-CoV Mac1 but not the closest human homologue, MacroD2. Our study demonstrates the feasibility of identifying selective inhibitors based on ADP-ribosylhydrolase activity, paving the way for the screening of large compound libraries to identify improved macrodomain inhibitors and to explore their potential as antiviral therapies for SARS-CoV-2 and future viral threats.